TITLE

NIH review to suggest streamlined handling of gene therapy bids

AUTHOR(S)
Taylor, Robert
PUB. DATE
June 1995
SOURCE
Nature;6/29/1995, Vol. 375 Issue 6534, p713
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the conclusion made by an external advisory panel that the Recombinant DNA Advisory Committee (RAC) of the United States National Institutes of Health (NIH) need not review human gene therapy protocols similar to those already approved. Initial screening of applications to be made within the Office of Recombinant DNA Activities (ORDA); Other conclusions made by the panel.
ACCESSION #
9508026810

 

Related Articles

  • In sickness and in health. Boyce, Nell // New Scientist;10/25/97, Vol. 156 Issue 2105, p20 

    Reports on the impact of gene therapy trials approved by the Recombinant DNA Advisory Committee of the US National Institutes of Health. Debate on the prevention of genetic engineering that changes normal characteristics; Effect of gene therapy on future generations; Risks of altering genetic...

  • Keeping faith in gene manipulation.  // Nature;7/18/1996, Vol. 382 Issue 6588, p191 

    Asserts that good reasons exist for revising the way the gene therapy experiments receive public scrutiny, but such revision must be done sensitively. The controversial role in the scientific community of the Recombinant DNA Advisory Committee (RAC) of the US National Institutes of Health...

  • US plan to scrap DNA panel splits genetic researchers. Wadman, Meredith // Nature;7/18/1996, Vol. 382 Issue 6588, p197 

    Reports disputes in the American gene-therapy field over a proposal to eliminate the Recombinant DNA Advisory Committee (RAC) of the US National Institutes of Health (NIH). Creation of the committee in the mid-1970s, in response to public fears of genetic engineering; The NIH's view that the...

  • Gene therapy approval may be rocky road for industry. Gavaghan, Helen // Nature;3/16/1995, Vol. 374 Issue 6519, p202 

    Talks about the possibility of a tough relationship to be faced by the biotechnology industry and Recombinant DNA Advisory Committee of the US National Institute of Health as the gene therapy moves down the clinical pipeline in US.

  • NIH panel may increase gene-trial scrutiny. . . Smaglik, Paul // Nature;6/15/2000, Vol. 405 Issue 6788, p724 

    Reports on the urgency of regulations to be placed on clinical trials for gene therapy. Decision made by the United States National Institutes of Health (NIH) to give its Recombinant DNA Advisory Committee (RAC) a greater role in the regulation process; Proposal that trial enrollment be...

  • NIH panel to limit secrecy on gene therapy. Wadman, Meredith // Nature;11/4/1999, Vol. 402 Issue 6757, p6 

    Reports actions taken by the Recombinant DNA Advisory Committee (RAC) to stiffen its guidelines on the reporting of deaths and adverse events in cases involving gene therapy patients. Why the branch of the National Institutes of Health (NIH) felt it needed to stiffen the guidelines; Response of...

  • Fertile is fine. Boyce, Nell // New Scientist;03/20/99, Vol. 161 Issue 2178, p22 

    Reports the reconsideration by the United States Food and Drug Administration (FDA) on a policy of restricting gene testing on sterile people. Allowances for gene therapy; Details of tests on animals using viruses or other vectors to deliver therapeutic DNA; Attack of the policy at a March 1999...

  • Researchers seek guidance on "preproposal" for in utero gene therapy. Jenks, Susan; Jenks, S // JNCI: Journal of the National Cancer Institute;10/21/98, Vol. 90 Issue 20, p1507 

    Presents information on a `preproposal' for in utreo gene therapy, which is being discussed before the Recombinant DNA Advisory Committee (RAC) by W. French Anderson, of the University of Southern California and Esmail Zanjani, of the University of Nevada. Information on gene therapy; Details...

  • Review panel cancels meeting as gene therapy proposals fall. Wadman, Meredith // Nature;2/22/1996, Vol. 379 Issue 6567, p668 

    Presents the reasons for the decline in gene therapy protocols. Cancellation of the March 1996 meeting by the 25-member Recombinant DNA Advisory Committee on the grounds that it does not have any protocols to review; Explanation of the decline as the pause in research as it moves from one level...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics